Trevi Therapeutics, Inc. Interest Expense Nonoperating
Trevi Therapeutics, Inc. (TRVI) reported Interest Expense Nonoperating of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-03-17
- Trevi Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. interest expense nonoperating for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Trevi Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $4.00K, a 98.98% decline from fiscal 2023.
- Trevi Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $391.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $1.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $1.00K derived: sum of 3 quarters · filed 2026-03-17 | $2.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-17 | $1.00K derived: sum of 2 quarters · filed 2026-03-17 | $2.00K derived: sum of 3 quarters · filed 2026-03-17 | $3.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.00K derived: sum of 2 quarters · filed 2026-03-17 | $3.00K derived: sum of 3 quarters · filed 2026-03-17 | $4.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.00K 10-Q · filed 2025-11-13 | $2.00K derived: sum of 2 quarters · filed 2025-11-13 | $3.00K 10-Q · filed 2025-11-13 | $7.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.00K 10-Q · filed 2025-08-07 | $2.00K 10-Q · filed 2025-08-07 | $6.00K derived: sum of 3 quarters · filed 2025-08-07 | $9.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.00K 10-Q · filed 2025-05-08 | $5.00K derived: sum of 2 quarters · filed 2025-05-08 | $8.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $7.00K derived: sum of 2 quarters · filed 2025-03-18 | $391.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $3.00K 10-Q · filed 2024-11-06 | $387.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |